To evaluate drug expenditure in healthcare, Vizient collected medication spend data from its pharmacy program clients, including hospital, non-acute and pediatric care providers. The information below spans from April 2023 to March 2024.
The top 10 infectious disease treatments by spend, along with their approved indications:
1. Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) — HIV-1
2. Prevnar 20 (pneumococcal 20-valent vaccine) — Prevention of pneumococcal disease
3. Veklury (remdesivir) — COVID-19
4. Gardasil 9 (human papillomavirus vaccine, 9-valent vaccine) — Prevention of HPV disease
5. Epclusa (sofosbuvir/velpatasvir) — Hepatitis C
6. Xifaxan (rifaximin) — Traveler’s diarrhea, hepatic encephalopathy
7. Shingrix — Prevention of herpes zoster
8. Mavyret (glecaprevir/pibrentasvir) — Hepatitis C
9. Boostrix — Prevention of diphtheria, pertussis, tetanus
10. Ambisome (amphotericin B liposome) — Fungal infections
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
